Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.62 |
| ▸ | APOBEC3B | Q9UH17 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901378 | 0.93 | CYP2C9 (0.62) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL1898383 | 0.89 | APOBEC3G (0.77) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL1901858 | 0.85 | APOBEC3G (0.56) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL1898793 | 0.85 | L3MBTL1 (0.59) | CYP2C9MAPTGAAMEN1KMT2A | |
| SCHEMBL1899898 | 0.83 | APOBEC3G (0.56) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL1898854 | 0.83 | MAPT (0.74) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL1901939 | 0.79 | CYP2C9 (0.69) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL27848704 | 0.78 | CYP2C9 (0.72) | CYP2C9MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1899341 | 0.77 | APOBEC3G (0.64) | APOBEC3GCYP2C9APOBEC3AAPOBEC3BMAPT | |
| SCHEMBL22542789 | 0.76 | CYP2C9 (0.74) | CYP2C9MAPTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | APOBEC3G 4852/4885CYP2C9 2835/4885APOBEC3A 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.